Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...
ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...
Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs
The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...
Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics
The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...
Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments
Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...
Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...
Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast
Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...
Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment
Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...
United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...
BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02
BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...
Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership
Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...
CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative...